Effects of N-acetylcysteine on cognitive function in chronic schizophrenia
Not Applicable
- Conditions
- Schizophrenia
- Registration Number
- JPRN-UMIN000013755
- Lead Sponsor
- Department of neuropsychiatry, St. Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
i) comorbid central nervous system disorder ii) meeting the DSM-IV-TR criteria for current and/or past alcohol or other substance dependence or abuse iii) meeting the DSM-IV-TR criteria for mental retardation iv) taking tricyclic antidepressants v) treatment with electroconvulsive therapy within the 12 weeks preceding the study vi) treatment with lithium, valproic acid, carbamazepine vii) patients who were not voluntarily hospitalized viii) active expression of suicidal ideation ix) pregnancy or breast feeding x) inability to understand the study protocol or being judged as uncooperative by the rater.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PANSS (Positive And Negative Syndrome Scale), BACS-J(Brief Assessment of Cognition in Schizophrenia-Japanese version)
- Secondary Outcome Measures
Name Time Method Magnetic resonance spectroscopy, Schizophrenia Cognition Rating Scale (SCoRS), UCSD Performance-based Skills Assessment-Brief (UPSA-B), Schizophrenia Quality of Life Scale-Japanese version (SQLS-J), Clinical Global Impression-Severity (CGI-S), Drug-Induced Extrapyramidal Symptoms Scale(DIEPSS), laboratory data